UMIN ID: UMIN000001446
Registered date:21/10/2008
Dose-escalation study of adjuvant vinorelbine plus cisplatin with Japanese completely resected stage I-IIIA non-small-cell lung cancer
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Patients with completely resected non-small-cell lung cancer with stage IB-IIIA and stage IA with 2cm or more |
| Date of first enrollment | 2008/06/01 |
| Target sample size | 9 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Level 1: Vinorelbin (20mg/m2)+Cisplatin (40mg/m2) Level 2: Vinorelbin (25mg/m2)+Cisplatin (40mg/m2) Level 3: Vinorelbin (25mg/m2)+Cisplatin (45mg/m2) |
Outcome(s)
| Primary Outcome | Maximum tolerance dose |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 18years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | 1.inadequate conditon for chemotherapy 2.Patients with a histoly of concurrent malignancy sidease were excluded |
Related Information
| Primary Sponsor | Hamamatsu Medical Cencer |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | none |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Kazuhito Funai |
| Address | Japan |
| Telephone | |
| kfunai@hmedc.or.jp | |
| Affiliation | Hamamatsu Medicar Cencer Thoracic surgery |
| scientific contact | |
| Name | Shigeru Momiki |
| Address | 328, Tomiduka, Naka, Hamamatsu, Shizuoka, Japan Japan |
| Telephone | |
| Affiliation | Hamamatsu medicar cencer Division of Thoracic Surgery |